Governance Exelixis, Inc.

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
43.96 ^USD	-3.26%		-0.18%	+0.30%

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Executive Committee: Exelixis, Inc.

Manager

Positions heldSince

Michael Morrissey

65 year

Chief Executive Officer	22/07/2010
President	22/07/2010

Christopher Senner

58 year

Director of Finance/CFO

15/07/2015

Dana Aftab

63 year

Chief Tech/Sci/R&D Officer

15/12/2022

Susan T. Hubbard

Investor Relations Contact	01/12/2016
Public Communications Contact	01/12/2016

Brenda Hefti

General Counsel

07/11/2025

Composition of the Board of Directors: Exelixis, Inc.

Director

CommitteesSince

Stelios Papadopoulos

77 year

Audit Committee	03/03/2025
Compensation Committee	03/03/2025

Jack Wyszomierski

69 year

Governance Committee	01/02/2004
Audit Committee Chair	01/02/2004
Audit Committee	01/04/2016
Compensation Committee	07/01/2024
Governance Committee Chair	01/04/2016
Nominating Committee Chair	01/04/2016

Julie Smith

55 year

Audit Committee	05/09/2018
Compensation Committee Chair	25/05/2022
Compensation Committee	04/06/2020
Governance Committee	04/06/2020
Nominating Committee	04/06/2020

Maria Freire

71 year

Governance Committee
Nominating Committee	09/05/2012
Governance Committee Chair
Compensation Committee	02/06/2021

Michael Morrissey

65 year

Audit Committee	24/05/2022
Governance Committee	24/05/2022
Nominating Committee	24/05/2022

Mary Beckerle

71 year

Governance Committee	05/01/2024
Nominating Committee
Governance Committee Chair

Robert Oliver

67 year

Audit Committee	21/04/2021
Compensation Committee	31/05/2023

S. Gail Eckhardt

68 year

Compensation Committee

05/01/2024

Tomas Jan Heyman

70 year

Governance Committee

31/05/2023

David Johnson

43 year

Audit Committee

31/05/2023

George Poste

82 year

Director/Board Member	01/08/2004
Independent Dir/Board Member	01/08/2004

Latest Appointments: Exelixis, Inc.

09/01	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
07/01	Enliven Therapeutics, Inc. Announces Changes in Board, Effective January 7, 2026	CI
08/11	Exelixis, Inc. Announces Executive Changes, Effective November 7, 2025	CI
30/25/30	Exelixis announces appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development	RE
30/25/30	Exelixis, Inc. Appoints Dana T. Aftab as Its Executive Vice President, Research and Development	CI
04/25/04	Kalaris Therapeutics, Inc. Appoints Leone Patterson to Its Board of Directors and as Chair of the Board?s Audit Committee	CI
16/24/16	C4 Therapeutics Names Paige Mahaney as Chief Scientific Officer	MT

More news

Former Officers and Directors: Exelixis, Inc.

Insider

Positions held

SinceUntil

Jeffrey Hessekiel

General Counsel	10/02/2014	07/11/2025
Corporate Secretary	01/10/2014	01/09/2024

Alan Garber

Director/Board Member	01/01/2005	30/05/2024
Independent Dir/Board Member	01/01/2005	30/05/2024

Carl Feldbaum

Director/Board Member	08/02/2007	31/05/2023
Independent Dir/Board Member	08/02/2007	31/05/2023

Vincent Marchesi

Director/Board Member	01/05/2001	31/05/2023
Independent Dir/Board Member	01/05/2001	31/05/2023

Lance Willsey

Director/Board Member	01/04/1997	07/05/2023
Independent Dir/Board Member	01/04/1997	07/05/2023

Charles M. Cohen

Director/Board Member	01/11/1995	25/05/2022
Independent Dir/Board Member	01/11/1995	25/05/2022

Gisela Schwab

Chief Tech/Sci/R&D Officer

01/09/2016

05/09/2021

George Scangos

Director/Board Member	01/10/1996	20/05/2020
Chief Executive Officer	01/10/1996	01/07/2010
President	01/10/1996	01/07/2010

Jonathan Berndt

Sales & Marketing

24/09/2015

Gregg Bernier

Sales & Marketing

24/09/2015

William Berg

Corporate Officer/Principal

24/09/2015

Arthur P. DeCillis

Chief Tech/Sci/R&D Officer

29/05/2007

01/01/2015

Kirk Rosemark

Corporate Officer/Principal

01/07/2003

01/11/2014

J. Garland

Corporate Officer/Principal

27/10/2011

31/10/2014

Frank Karbe

Director of Finance/CFO

01/02/2004

02/06/2014

Francis McCormick

Director/Board Member	01/07/2003	28/05/2014
Independent Dir/Board Member	01/07/2003	28/05/2014

Qin Hua Ru

Director/Board Member

01/01/2013

01/01/2014

James Bucher

General Counsel	01/01/2007	01/01/2014
Corporate Secretary	01/01/2007	01/01/2014

F. Michael Yakes

Corporate Officer/Principal

01/01/2012

Lupe M. Rivera

Chief Operating Officer

01/01/2002

01/09/2011

John Nuss

Corporate Officer/Principal

21/09/2009

01/04/2011

Natalie Sacks

Chief Tech/Sci/R&D Officer

01/09/2009

01/03/2011

Patrick Rivers

Corporate Officer/Principal

01/05/2009

01/01/2011

Larry Mattheakis

Corporate Officer/Principal

01/01/2007

01/01/2011

Leone Patterson

Corporate Officer/Principal

01/07/2007

01/11/2010

Jeff P. Coon

Human Resources Officer

01/01/2008

01/01/2009

Ronald Shazer

Corporate Officer/Principal

01/03/2007

01/01/2009

Anne Champsaur

Corporate Officer/Principal

29/05/2007

Christoph Pereira

General Counsel	01/06/2004	01/03/2007
Corporate Secretary	01/06/2004	01/03/2007

Jeffrey R. Latts

Corporate Officer/Principal

01/07/2001

12/01/2007

S. Michael Imperiale

Corporate Officer/Principal

01/01/2004

01/01/2006

Laura Dillard

Human Resources Officer

01/11/2014

Kristine Ball

Director of Finance/CFO

01/01/2000

01/01/2005

Angie You

Corporate Officer/Principal

31/12/2004

Jane M. Green

Public Communications Contact

01/09/2004

Jerome Dvonch

Corporate Officer/Principal

01/09/2000

01/06/2004

Steven James

Corporate Officer/Principal

01/01/2003

01/01/2004

Glen Y. Sato

Director of Finance/CFO	01/11/1999	-
General Counsel	01/11/1999	-

Kimberly Manhard

General Counsel

01/01/2002

01/01/2003

Najafi Behrooz

Corporate Officer/Principal

01/01/1996

01/01/2003

Geoff Duyk

Director/Board Member	01/01/1996	-
Chief Tech/Sci/R&D Officer	01/01/1996	-
Corporate Officer/Principal	01/01/1996	01/01/2003

Yifan Zhai

Corporate Officer/Principal

01/01/2001

01/01/2003

Robert M. Myers

Corporate Officer/Principal

01/01/2002

01/01/2003

Deborah Burke

Comptroller/Controller/Auditor	01/05/2005	-
Director of Finance/CFO	01/05/2005	15/07/2015

Casey C. Kopczynski

Chief Tech/Sci/R&D Officer

01/01/1996

01/01/2002

Pamela A. Simonton

General Counsel	01/04/2000	13/02/2014
Corporate Officer/Principal	13/02/2014	-

William Waddill

Chief Administrative Officer	01/12/1996	01/02/2000
Director of Finance/CFO	01/12/1996	01/02/2000

Stephen Doberstein

Corporate Officer/Principal

01/01/1997

David Matthews

Corporate Officer/Principal

01/01/1999

Remi Barbier

Chief Operating Officer

01/01/1996

01/05/1998

Camille DeLuca-Flaherty

Corporate Officer/Principal

01/01/1998

Corey Goodman

Founder

15/11/1994

Jason S. Fisherman

Director/Board Member

Wayne Montgomery

Corporate Officer/Principal

Jean-Francois Formela

Director/Board Member

William J. Spencer

Director/Board Member

Charles Butler

Investor Relations Contact	27/10/2011	-
Public Communications Contact	-	-

Michael J. Jeffrey

Director/Board Member

Lisa Stemmerich

Human Resources Officer

Richard Buller

Corporate Officer/Principal

Jonathan Lightner

Corporate Officer/Principal

Douglas I. Buckley

Corporate Officer/Principal

Tielin Wang

Corporate Officer/Principal

Karin Schmitt

Corporate Officer/Principal

Ho Sung Cho

Corporate Officer/Principal

Cheni Kwok

Corporate Officer/Principal

Soleil Maxwell Harrison

Public Communications Contact

11/06/2009

Angela Bitting

Public Communications Contact

25/06/2009

Scott Ogg

Chief Tech/Sci/R&D Officer

René Castro

Corporate Officer/Principal

Gregory D. Plowman

Chief Tech/Sci/R&D Officer

Paulette A. Dillon

Sales & Marketing

Hal Mackins

Public Communications Contact

Hartmut Tintrup

Corporate Officer/Principal

Harold Keer

Chief Tech/Sci/R&D Officer	06/07/2011	-
Corporate Officer/Principal	-	06/07/2011

Xiao Hui Gu

Corporate Officer/Principal

Tao Wang

Corporate Officer/Principal

José Baselga

Director/Board Member

Andrew C. Lam

Corporate Officer/Principal

Lloyd M. Kunimoto

Corporate Officer/Principal

Yuling Luo

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	16
Female	3

Of which Executive Committee

Male	4
Female	1

Of which Directors

Male	10
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Employees

1,147

Sector

Biotechnology & Medical Research

Calendar

10/02 - Q4 2025 Earnings Release (Projected)

More about the company